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Abbreviations 
PMD Pelizaeus-Merzbacher disease 
MRS magnetic resonance spectroscopy 
PLP1 proteolipid protein 1 
MRI magnetic resonance imaging 
CNS central nervous system 
GABA -aminobutyric acid 
ABR auditory brainstem response 
PRESS Point Resolved Spectroscopy 
CHESS chemical shift-selective 
TR repetition time 
TE echo time 
ROI region of interest 
NAA N-acetyl aspartate 
Glu glutamate 
%SD  percent standard deviation  
STEAM stimulated echo acquisition mode  
Cho  choline-containing compounds 
Cr  creatinine  






In this report, we describe a patient with Pelizaeus-Merzbacher disease (PMD) who 
underwent repeated evaluations by 1H-Magnetic resonance spectroscopy (MRS) . 
Subject: 
The patient was given a definitive diagnosis of PMD based on genetic testing, which 
showed overlap of the proteolipid protein 1 (PLP1) gene.  The control subjects for 
1H-MRS consisted of healthy age-matched children. 
Methods: 
All measurements were performed with a clinical 3-tesla magnetic resonance imaging 
(MRI) system.  For 1H-MRS, the center of a voxel was positioned in the right parietal 
lobe.  1H-MRS was performed when the patient was 2, 6, 14, and 25 months old.   
Results: 
The concentration of GABA in early childhood (2 months 1.72 mM, 6 months 2.15 mM) 
was increased compared with that in normal controls.  However, his GABA 
concentration was normalized at 14 and 25 months.  The concentrations of Ins were 
increased after 6 months.  No remarkable changes were seen in the concentration of 
Cho at any time. 
Conclusion 
These results suggest that the changes in metabolite concentrations during growth may 
reflect the pathological state of PMD.  Furthermore, the lack of a change in the Cho 
concentration may be useful for differentiating PMD from other demyelinating diseases. 
  
Introduction 
Pelizaeus–Merzbacher disease (PMD) is a rare, X-linked dysmyelinating disorder of the 
central nervous system (CNS) that induces congenital nystagmus beginning in the first 
year of life, delayed achievement of motor and cognitive milestones, spastic paralysis, 
ataxia and seizures.  In contrast to other demyelinating leukodystrophies, such as 
metachromatic leukodystrophy and adrenoleukodystrophy, in which myelin is formed 
but subsequently destroyed, PMD is characterized by a failure of myelin to form.  PMD 
is caused by alteration of the gene that encodes proteolipid protein 1 (PLP1), one of the 
most abundant proteins in CNS myelin [1,2].  In PMD, magnetic resonance imaging 
(MRI) generally shows either diffuse or patchy (tigroid) T2 hyperintensity in the 
cerebellar, brain stem, and supratentorial white matter.  This appearance is believed 
to be the result of the lack of formation of myelin (hypomyelination or dysmyelination) 
[3].  However, based on MRI findings alone, it is difficult to differentiate PMD from 
other forms of white-matter degeneration, such as leukodystrophy.  1H-Magnetic 
resonance spectroscopy (MRS) may be useful for evaluating the degree of white-matter 
degeneration.  However, there have been few reports on the use of 1H-MRS in PMD, 
and the results have varied.  To our knowledge, there has been no report on the 
application of 1H-MRS to determine the -aminobutyric acid (GABA) concentration in 
PMD patients.   
In this report, we describe a patient with PMD who underwent repeated 1H-MRS for the 
evaluation of changes over time. 
Case  
At birth, the patient weighed 2178g and his gestational age was 38 weeks 3 days.  
There were no abnormal episodes in the perinatal period.  There were no abnormalities 
by Guthrie testing or an acylcarnitine analysis.  His family history was unremarkable. 
Horizontal nystagmus was noted beginning at one month after birth.  This symptom 
persisted, and his parents consulted our hospital when he was 2 months old.  In the 
auditory brainstem response (ABR), only a wave I was seen on both sides, and thus we 
suspected PMD.  
At age 7 months, a clear delay of myelinization was observed in MRI(Figure), and the 
ABR abnormality persisted.  Therefore, genetic testing was performed for the PLP1 
gene.  The results showed duplication of the PLP1 gene, and therefore he was given a 
definitive diagnosis of PMD. 
The patient is currently age 2 year 9 months.  He can maintain a seated position with 




1H-MRS was performed when the patient was 2, 6, 14, 25 and months old.  The control 
subjects for 1H-MRS consisted of age-matched children (Group 1: 9 children, 2-11 
months old (mean 5.9 months), Group 2: 10 children, 12-26 months old (mean 18.3 
months)).  All measurements were performed with a clinical 3-tesla MR imager (Signa 
3T HD, GE Medical Systems, Milwaukee, WI, USA) using a standard quadrature head 
coil for MRI and 1H-MRS measurements.  All subjects were treated with triclofos 
sodium (Tricloryl; 0.5 ml/kg body weight) for sedation one hour before the MR 
examination.  For 1H-MRS, the center of a voxel was positioned in the right parietal 
lobe.  
MEGA was incorporated into Point Resolved Spectroscopy (PRESS) consistent with 
the protocol established in previous reports [4,5].  Water suppression was carried out 
using conventional three chemical shift-selective (CHESS) pulses after manual 
optimization, and was achieved at a level of less than 1%.  Gradient map shimming 
was conducted in the measurement location by the high-order shim program, and the 
full width at half maximum of the water peak was less than 7 Hz.  The sequence 
parameters were as follows: repetition time (TR) = 1500 ms, echo time (TE) = 68 ms, 
region of interest (ROI) = 3×3×3 cm3 (27 ml), summation = 128 signals for each 
spectrum, total acquisition time = 12 minutes.  Measurements with and without 
frequency-selective pulses were conducted alternatively, i.e., J evolution for GABA was 
refocused during odd-numbered acquisitions, and was not refocused during 
even-numbered acquisitions.  Phase correction was conducted for each spectrum.  
Differences in the acquired spectra provided an edited spectrum for GABA.  The in 
vitro data for N-acetyl aspartate (NAA), glutamate (Glu), and GABA were acquired with 
MEGA-PRESS with the same parameters as for human measurements and set 
according to the LCModel basis set.  The signals in the difference spectra obtained by 
MEGA-PRESS were analyzed by LCModel (version 6.1) with our original basis set for 
MEGA-PRESS, and the quantified concentration of GABA was confirmed in a phantom 
study with known concentrations of metabolites. The criteria for selecting reliable 
metabolite concentrations were based on the percent standard deviation (%SD) of the fit 
for each metabolite that reflected the Cramer-Rao lower bounds.  Only results with 
a %SD <15% were included in the analysis.  
The parameters of the conventional stimulated echo acquisition mode (STEAM) 
sequence were as follows: TR = 5000 ms, TE = 15 ms, ROI = 1.5×2.0×2.0 cm3 (6.0 ml), 
total acquisition time = 6.8 minutes.  We analyzed the metabolites, NAA, 
choline-containing compounds (Cho), creatinine(Cr), myoinositol (Ins), Glu, using the 
external standard calibration method in LCModel Ver 6.1. The %SD value of the fit for 
each metabolite that reflected the Cramer-Rao lower bounds was less than 15%.  The 
concentration of each metabolite was judged to be abnormal when the value was more 
than 2SD greater than or less than that in the control subjects. 
Informed consent was obtained from the family members of all of the children. 
  
Results (Table 1, Table 2, Figure) 
Metabolite concentrations in normal controls are shown in Table 1.  
In the PMD patient (Table 2), the NAA concentration increased with age. At age 6 
months, the NAA concentration was significantly higher than that in normal control 
subjects.  At 6, 14 and 25 months, the Cr, Ins and Glu concentrations in the PMD 
patient were increased compared to those at 2 months.  At 6 months, the Cr, and Glu 
concentrations were significantly higher than those in normal control subjects.  At 6, 
14, 25 months, the Ins concentrations were significantly higher than those in normal 
control subjects. 
At each age, there was no change in the Cho, concentration, and there was no 
significant difference compared to that in normal controls. 
The GABA concentration in the PMD patient was high at 2 and 6 months.  However, at 
14 and 25 months, the GABA concentration had decreased. The GABA concentration in 
the PMD patient was significantly different from that in normal controls at 2 and 6 
months. 
  
Discussion   
Table 3 shows 1H-MRS findings in PMD patients that have been reported to date [6-13].  
The results of 1H-MRS in PMD are somewhat varied. These differences in 1H-MRS 
findings may be due to  the age at which testing was performed,  the site of the 
examination, and/or  differences in the abnormality of the PLP1 gene.  However, 
Takanashi and Hanefeld recently reported that increases of NAA, Ins, and Cr were 
observed in PMD patients.  They also reported that there was either no change or a 
decrease in Cho in PMD patients.  Since these findings are similar to ours, they may be 
pathognomonic for PMD. 
In our PMD patient, the NAA concentration increased with age.  At age 6 months, the 
NAA concentration was significantly higher than that in normal control subjects.  
Pouwels et al. reported that the density of NAA in childhood increased with age [14], 
which is consistent with our results regarding a change in NAA with age by 1H-MRS.   
However, this does not explain why a significant increase was only observed at 6 
months.  There have been several reports on the increase in the NAA concentration in 
PMD [6,8].  Two possible explanations for this increase have been proposed.  First, 
this may be due to a disorder of axonal signal transduction as a result of myelination 
deficiency, which activates axonal metabolism. Second, this may be due to an increase in 
oligodendrocytic progenitor cells, which was confirmed in a murine model of PMD.  In 
our case, a significant increase was only observed at age 6 months, which reflects the 
distinguishing pathological condition of PMD at that age (i.e., activation of axonal 
metabolism). 
In our PMD patient, there was no change in the Cho concentration at each age, and 
there were no significant differences compared to the normal controls.  The 
concentration of Cho is believed to increase during the process of myelination, and in 
demyelinating diseases [6].  In comparison to mature oligodendrocytes, 
oligodendrocytic precursor cells and astrocytes have moderately low concentrations of 
Cho [15].  This lack of a change in the Cho concentration may reflect the pathological 
condition of PMD, which is a failure to form myelin, rather than demyelination. 
In our PMD patient, the Cr and Ins concentrations at 6 and 14 months were higher than 
those at 2 months. At 6 months, the Cr and Ins concentrations were significantly higher 
than those in normal control subjects.  Furthermore, the Ins concentrations were 
significantly higher than those in normal control subjects at 14 and 25 months. The 
total Cr concentration is a marker for the concentrations of neurons and glia cells.  An 
increased Cr concentration has recently been reported in the lesions of patients with 
multiple sclerosis (MS) [16].  The increased astrocytic activity associated with gliosis 
was considered to be responsible for the elevated Cr concentration in MS.  Ins has been 
shown to be a glia-specific marker, with a particularly high concentration in astrocytes 
[17].  The elevated Ins in MS has been speculated to be due to both the accumulation of 
myelin breakdown products during the acute phase and astrocytic gliosis in chronic 
lesions [6].  The former mechanism is not applicable to PMD because there is no active 
demyelination phase.  Therefore, the elevated Ins and Cr concentrations may result 
from astrocytic gliosis caused by chronic damage to axons. 
In our case, the Glu concentrations at 6 and 14 months were higher than that at 2 
months.  At 6 months, the Glu concentration was significantly higher than that in 
normal control subjects.  In one study, the glutamine (Gln) concentration in white 
matter of a PMD patient was significantly higher than that in normal control subjects 
[8].  The increase in Glu in PMD may reflect an increase in neurotransmitter caused by 
the activation of signal transduction which compensates for disordered axons with 
myelination deficiency. 
In our case, GABA concentrations were high up until age 6 months.  However, at 14 
and 25 months, the GABA concentration had decreased.  The GABA concentration in 
PMD was significantly different from that in normal controls at both 2 and 6 months.  
To our knowledge, there has been no previous report on the use of MRS to determine the 
GABA concentration in PMD patients.  A study in an animal model of PMD, the 
myelin-deficient (MD) rat, showed that it carries a point mutation in the PLP gene [18].  
Histologic examination of the caudal brainstem in the MD rat showed fewer GABA(A) 
receptors on neurons in the nucleus tractus solitarius, hypoglossal nucleus, and dorsal 
motor nucleus of the vagus.  In our case, the high GABA concentration by 1H-MRS may 
be due to compensation for the disorder of the GABA nervous system. 
Therefore, the changes in metabolite concentrations during growth may reflect the 
pathological state of PMD, such as a change in axonal signal transduction with 
myelination deficiency, an increase in oligodendrocytic progenitor cells, and astrocytic 
gliosis caused by axonal damage.  Furthermore, the lack of a change in the Cho 
concentration may be useful for differentiating PMD from other demyelinating diseases.  
However, our study considered only one subject.  To enhance the reliability of our 
findings, we must study a greater number of PMD patients. 
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Table 1  
Metabolite concentrations in normal controls by 1H-MRS. 
 
Group 1: 9 children, 2-11 months old (mean 5.9 months)  
 NAA Cr Cho Ins Glu GABA 
average 7.1 6.8 2.9 4.9 8.1 1.05 
standard 
deviation 
1.2 1.4 0.7 1.4 1.4 0.22 
 
Group 2: 10 children, 12-26 months old (mean 18.3 months) 
 NAA Cr Cho Ins Glu GABA 
average 8.8 7.9 2.4 4.4 9.1 1.28 
standard 
deviation 
1.3 1.2 0.4 0.9 1.8 0.35 
 
Table 2 
Result of 1H-MRS in the PMD patient. 
# more than 2SD greater or less than that in the control subjects. 
 
A: 2 months old 
 NAA Cr Cho Ins Glu GABA 
Concentration 5.5 5.6 2.3 4.8 6.5 # 1.72 
SD -1.3 -0.9 -0.9 -0.1 -1.1 # 3.0 
 
B: 6 months old 
 NAA Cr Cho Ins Glu GABA 
concentration # 9.7 9.4 2.7 # 8.1 # 12.0 # 2.15 
SD # 2.2 1.9 -0.3 # 2.3 # 2.8 # 4.90 
 
C: 14 months old 
 NAA Cr Cho Ins Glu GABA 
concentration 10.2 8.9 2.7 6.7 10.7 0.95 
SD 1.1 0.8 0.7 # 2.6 0.9 -0.93 
 
D: 25 months old 
 NAA Cr Cho Ins Glu GABA 
concentration 10.1 8.8 2.3 8.0 10.5 0.98 
SD 1.0 0.7 -0.3 # 4.1 0.8 -0.84 
 
 Table 3 
 1H-MRS findings in Pelizaeus-Merzbacher disease (PMD) reported to date. 
 
 Number of patients Age (year) Comments 
Takanashi J, et al. [6] 
Neurology 2002;58:237-241 ] 
5 4-10  NAA (16% increase), Cr (43% increase), Ins (31% increase) 
Cho: no change 
Takanashi J , et al. [7] 
AJNR 1997;18:533-535 
2 5,6 Normal MRS results, creatine levels tended to be elevated 
Hanefeld FA, et al. [8] 
Neurology 2005;65:701-706 
5 0.6-6.8 Increased tNAA, Gln, Ins, creatine, and phosphocreatine 
levels, Decreased Cho level 
Kurata K, et al. [9] 
No to hattatsu 2000;32:503-508 
3 25-34  No reduction in the NAA concentration. 
Pizzini F, et al. [10] 
AJNR 2003;24:1683-1689 
3 2-7 Decreased NAA level 
Increased Cho and Cr levels 
Grodd W, et al. [11] 
Radiology 1991; 181: 173–181. 
4 0.7-5.7 Increased Cho level and decreased NAA levels 
Spalice A, et al. [12] 
Pediatr. Radiol. 2000; 30: 171–175. 
2 1.5, 6 Decreased Cho level 
Bonavita S, et al. [13] 
Neurology 2001;56:785–788 
9 6–43 Decreased NAA level 

